作者:V. Ya. Degoda、B. R. Kiyak、V. S. Manzhara、V. E. Rodionov、A. I. Proskura
DOI:10.1007/bf02758061
日期:2000.5
The photoluminescence (PL), roentgenoluminescence (RL), and optical absorption of ZnSe were measured near the fundamental edge in the temperature range from 80 to 400 K. Because of the much smaller absorption coefficient for x-rays as compared to visible light, the contribution to RL from emitting centers located deeper in the sample is higher. The quality of ZnSe can be assessed by correlating its near-edge PL and RL spectra. The temperature dependences of the peak positions of the blue PL and RL bands indicate that these emissions are due to the same center. The blue RL band is redshifted by 18 meV in comparison with Pt,, and its intensity is lower than that of the longer wavelength bands. The different positions of the PL and RL bands are interpreted in terms of thermal spike formation under x-ray excitation and reabsorption of the emitted light.
Zur Kenntnis der Triterpene. (69. Mitteilung). Über die β-Elemonsäure
作者:L. Ruzicka、H. Häusermann、Ed. Rey
DOI:10.1002/hlca.19420250627
日期:1942.10.15
Zur Kenntnis der Triterpene. Überführung der tetracyclischen Elemadienolsäure in einen pentacyclischen Kohlenwasserstoff C<sub>30</sub>H<sub>50</sub>
作者:L. Ruzicka、A. Hiestand、H. Baumgartner、O. Jeger
DOI:10.1002/hlca.19470300728
日期:1947.12.1
SKIN ENGAGING MEMBER FOR RAZOR CARTRIDGE COMPRISING SKIN ACTIVE INGREDIENT
申请人:BIC Violex S.A.
公开号:EP3930668A1
公开(公告)日:2022-01-05
Modification of cyclooxygenase and lipoxygenase activity with asteridae extracts and optionally boswellic acid
申请人:Shaklee Corporation
公开号:US20040166182A1
公开(公告)日:2004-08-26
Extracts from plants in the Asteridae subfamily, such as
Carthamus tinctorious
, are effective to selectively inhibit COX-2 activity and/or enhance COX-1 activity. When Asteridae extracts are combined with boswellic acid, the combination exhibits a synergistic inhibitory effect on both COX-2 and LO. Such extracts and combinations are used in methods of selectively inhibiting COX-2, inhibiting LO, and/or enhancing COX-1 activity as well as in the methods of treating conditions that would respond favorably to any of these effects.